Reshape the Fates of Treg and CD8+T Cells Through IL‐2Rα by Synergizing Divergent Receptor‐Biased IL‐2 PEGylates

Reshape the Fates of Treg and CD8+T Cells Through IL‐2Rα by Synergizing Divergent Receptor‐Biased IL‐2 PEGylates

Abstract Clinical trials of receptor‐biased interleukin‐2 (IL‐2) variants in cancer therapy show limited efficacy. To investigate, we re‐evaluated divergent receptor‐biased IL‐2 PEGylates (generated via site‐specific PEGylation at residues D20 (not‐β) and Y45 (not‐α)), alone or in combination. Resul...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiaqi Sun, Lingfeng Guo, Dezhong Ji, Mengfan Yu, Boyang Cheng, Xingxing Zhu, Yeshuang Yuan, Siyu Wu, Yuanjie Zhang, Wen Shi, Zhiqian Chen, Xindang Chu, Jiayu Hu, Liwen Hua, Yiming Wang, Yanning Zhu, Yu Mu, Hanwen Sun, Chuanling Zhang, Qi Wang, Sulong Xiao, Lihe Zhang, Bo Zhang, Demin Zhou
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Advanced Science
Subjects:
CD8+ T
interleukin‐2
PEGylation
tumor immunotharapy
Online Access:https://doi.org/10.1002/advs.202414931
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/advs.202414931

Similar Items